Novo Nordisk and Hims & Hers reached an agreement under which Hims will offer Novo’s GLP‑1 medicines at standard telehealth prices and limit promotion of compounded alternatives. Novo agreed to drop its patent lawsuit while reserving future legal rights, and Hims will give patients the option to switch to FDA-approved products. The deal ends a monthslong confrontation over compounded GLP‑1 therapies that drew regulatory scrutiny. Novo described the agreement as expanding access to approved medicines; Hims’ pivot reduces legal and compliance risk for both companies while reshaping telehealth distribution dynamics for high-demand obesity and diabetes drugs.